研發(fā)創(chuàng)新
R&d innovation
-
First-in-human immunomodulation mechanism research of chlorogenic acid in patients with recurrent high-grade glioma
First-in-human immunomodulation mechanism research of chlorogenic acid in patients with recurrent high-grade glioma2018.04.27本研究首次探討了綠原酸在復(fù)發(fā)性高級(jí)別膠質(zhì)瘤患者中的免疫調(diào)節(jié)機(jī)制。研究納入6例患者，收集其綠原酸治療前后的外周血樣本，通過高通量RNA測(cè)序（RNA-seq）分析基因表達(dá)差異。結(jié)果顯示，2例患者（P3和P4）在綠原酸治療后達(dá)到疾病穩(wěn)定狀態(tài)，無進(jìn)展生存時(shí)間分別為8.1個(gè)月和4.9個(gè)月，總生存時(shí)間均為16.5個(gè)月，且至今仍存活。 -
Isolation and identification of human metabolites from a novel anti-tumor candidate drug 5-chlorogenic acid injection by HPLC-HRMS_MSn and HPLC-SPE-NMR
Isolation and identification of human metabolites from a novel anti-tumor candidate drug 5-chlorogenic acid injection by HPLC-HRMS_MSn and HPLC-SPE-NMR2017.09.20本研究對(duì)新型抗腫瘤藥物注射用綠原酸在人體內(nèi)的代謝產(chǎn)物進(jìn)行了分離和鑒定。研究中，健康成年人肌肉注射該藥后，收集其尿液和糞便樣本進(jìn)行分析。結(jié)果顯示，糞便中未檢測(cè)到代謝產(chǎn)物，而尿液中共鑒定出6種代謝產(chǎn)物，包括異構(gòu)化綠原酸、水解綠原酸以及甲基化綠原酸（M3和M4），其中M3和M4為主要代謝產(chǎn)物。
-
Chlorogenic acid inhibits glioblastoma growth through repolarizating macrophage from M2 to M1 phenotype
Chlorogenic acid inhibits glioblastoma growth through repolarizating macrophage from M2 to M1 phenotype2017.01.05本文研究了綠原酸（CHA）通過將腫瘤相關(guān)巨噬細(xì)胞從促腫瘤的M2表型極化為抗腫瘤的M1表型，從而抑制膠質(zhì)母細(xì)胞瘤生長(zhǎng)的機(jī)制。研究發(fā)現(xiàn)，CHA通過促進(jìn)STAT1信號(hào)通路激活和抑制STAT6信號(hào)通路激活來調(diào)節(jié)巨噬細(xì)胞的極化狀態(tài)。